News

Scientists Grow Mature Nerve Cells From Stem Cells

Scientists have developed a new method that allows them to grow mature nerve cells from stem cells — a technique that could be applied to study diseases like amyotrophic lateral sclerosis (ALS). “For the first time, we have been able to see adult-onset neurological protein aggregation in the stem…

ANX005 Slows ALS Progression in Phase 2a Study

ANX005, an experimental medication being developed by Annexon Biosciences for neurodegenerative and autoimmune diseases, resulted in a slowing of disease progression in adults with amyotrophic lateral sclerosis (ALS). That’s according to preliminary data from eight patients taking part in a Phase 2a clinical study (NCT04569435), whose main…

Probiotic Prevents Neurodegeneration in ALS Worm Models

The bacterial strain Lacticaseibacillus rhamnosus HA-114 prevents neurodegeneration and preserves motor function in worm models of amyotrophic lateral sclerosis (ALS), a new study reports. This protective effect was linked to the fat molecules, called fatty acids, found in this strain, which helped restore fat metabolism in the mitochondria —…

Dosing Starts in First-in-human Phase 1 Trial of QRL-101 for ALS

A Phase 1 clinical trial has begun dosing adult healthy volunteers to investigate QurAlis Corporation‘s QRL-101, an oral treatment candidate for amyotrophic lateral sclerosis (ALS), the company announced. The first-in-human Phase 1 trial (NCT05667779) aims to assess the safety, tolerability, and pharmacokinetics — the movement of a…

Masitinib Gains Orphan Drug Status for ALS in Switzerland

Masitinib, an oral medicine developed by AB Science, has won orphan drug status for treating amyotrophic lateral sclerosis (ALS) in Switzerland. The status is granted by the Swiss Agency for Therapeutic Products (Swissmedic) to therapies that seek to treat life-threatening or chronic diseases affecting no more than…